Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis.
Anand AC, Nandi B, Acharya SK, Arora A, Babu S, Batra Y, Chawla YK, Chowdhury A, Chaoudhuri A, Eapen EC, Devarbhavi H, Dhiman R, Datta Gupta S, Duseja A, Jothimani D, Kapoor D, Kar P, Khuroo MS, Kumar A, Madan K, Mallick B, Maiwall R, Mohan N, Nagral A, Nath P, Panigrahi SC, Pawar A, Philips CA, Prahraj D, Puri P, Rastogi A, Saraswat VA, Saigal S, Shalimar, Shukla A, Singh SP, Verghese T, Wadhawan M; INASL Task-Force on Acute Liver Failure.
ACR Appropriateness Criteria® Abnormal Liver Function Tests.
Expert Panel on Gastrointestinal Imaging; Arif-Tiwari H, Porter KK, Kamel IR, Bashir MR, Fung A, Kaplan DE, McGuire BM, Russo GK, Smith EN, Solnes LB, Thakrar KH, Vij A, Wahab SA, Wardrop RM 3rd, Zaheer A, Carucci LR.
J Am Coll Radiol. 2023 Nov;20(11S):S302-S314. doi: 10.1016/j.jacr.2023.08.023.
PMID:38040457
Antithyroid Agents.
[No authors listed]
2014 Feb 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
PMID:31643916
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184. Epub 2018 Jun 15.
PMID:29906252
Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A, Lanthier N, Dano H, Aydin S, Leggenhager D, Weber A, Dekairelle AF, De Cuyper A, Gala JL, Humblet Y, Sempoux C, Van den Eynde M.
Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19.
Röttele F, Zollner A, Mogler C, Yuksel M, Arikan C, Karl V, Aberle JH, Aberle SW, Kogler H, Vécsei A, Vodopiutz J, Salié H, Gräser A, Krimmel L, Martin P, Lurz E, Maier FI, Woelfle L, Nobre S, Goncalves I, Kern L, Schwemmle M, Boettler T, Hofmann M, Hasselblatt P, Thimme R, Tilg H, Müller T, Vogel GF, Bengsch B.
Gut. 2025 Aug 7;74(9):1486-1499. doi: 10.1136/gutjnl-2024-333880.
PMID:40187893
[Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)].
Chinese Medical Association Tuberculosis Branch.
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Nov 12;47(11):1069-1090. doi: 10.3760/cma.j.cn112147-20240614-00338.